Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy.

作者信息

Gurney Mark, Baranwal Anmol, Rosenthal Allison, Kharfan-Dabaja Mohamed A, Kenderian Saad S, Lin Yi, Shah Mithun Vinod

机构信息

Division of Hematology, Mayo Clinic, Rochester, Minnesota.

Cancer Centers of Southwest Oklahoma, Lawton.

出版信息

JAMA Oncol. 2024 Apr 1;10(4):532-535. doi: 10.1001/jamaoncol.2023.7182.

DOI:10.1001/jamaoncol.2023.7182

PMID:38386311

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10884941/

Abstract

摘要

相似文献

[1]

Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy.

JAMA Oncol. 2024-4-1

[2]

Chimeric Antigen Receptor T-Cell Therapy for Patients With Multiple Myeloma-A Call for Equal Opportunity.

JAMA Oncol. 2023-3-1

[3]

Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods.

Balkan Med J. 2025-7-1

[4]

Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy.

Nat Cancer. 2025-4

[5]

Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment.

Bone Marrow Transplant. 2020-11

[6]

Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.

Lancet Haematol. 2025-5

[7]

Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma.

Clin Cancer Res. 2025-3-17

[8]

Long-term outcomes following CAR T cell therapy: what we know so far.

Nat Rev Clin Oncol. 2023-6

[9]

Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors.

J Immunother Cancer. 2023-3

[10]

Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.

Transplant Cell Ther. 2022-6

引用本文的文献

[1]

Deep insight into cytokine storm: from pathogenesis to treatment.

Signal Transduct Target Ther. 2025-4-16

[2]

TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.

Am J Hematol. 2025-6

[3]

Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study.

Bone Marrow Transplant. 2025-5

[4]

A Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies.

Med Sci Monit. 2025-2-2

[5]

CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review.

JAMA. 2024-12-10

[6]

Blood Cancer Discov. 2024-11-1

[7]

Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients.

Clin Cancer Res. 2024-10-15

[8]

Current progress in CAR-based therapy for kidney disease.

Front Immunol. 2024

[9]

Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.

Front Oncol. 2024-6-11

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

引用本文的文献